Access To Medicines

Public Citizen's Global Access to Medicines Program works with partners worldwide to improve health outcomes and save lives, through use of pharmaceutical cost-lowering measures including generic competition. We support civil society groups and public agencies with analysis and technical assistance to help overcome patent-based and other drug monopolies. Our work challenges Big Pharma's economic and political power. Learn more about the Access to Medicines Program

What's New? Peru launches the "No Negociable, TPP: Todos Podemos Perder" campaign for TPP Round 17 happening in Lima this week. See updates here

 

 

 

RECENT NEWS: Indonesia Licenses 7 HIV and Hep B medicines


What's New 

May 23, 2013- New Vision: Civil Society groups petition US, EU over WTO TRIPS Agreement (links to newvision.co.ug)

May 20, 2013- Huffington Post: TRIPS Exemption Opposed by Obama Administration, Threatening Cost Spike for Drugs in Poorest Nations (links to huffingtonpost.com)

May 18, 2013-Huffington Post Canada: Why Are We Bullying the World's Poorest Countries? (links to huffingtonpost.ca)

May 15, 2013
- The Atlantic: How Drug Companies Keep Medicine Out of Reach (links to theatlantic.com)

May 15, 2013-Members of Congress urge USTR to support request from least developed countries for a TRIPS waiver extension

May 14, 2013
- The New Nation: US, EU urged to keep TRIPS waiver open (links to thenewnation.bd.com)

May 2, 2013-CitizenVox: US Government's "Watch List" on Developing Countries Health Rights (links to citizenvox.com)

May 1, 2013-
The New York Times: Exorbitant Prices for Cancer Drugs (links to nytimes.com)

April 25, 2013
- Blood Journal: Prices of drugs for chronic myeloid leukemia (CML), reflection of the unsustaintable cancer drug prices: perspective of CML experts (links to bloodjournal.hematologylibrary.org)

April 25, 2013- New York Times: Doctors Denounce Cancer Drug Prices of $100, 000 A Year (links to nytimes.com)

April 23, 2013- Wall Street Journal Op-Ed: Must All Patents Last for 20 Years? (links to online.wsj.com)

April 1, 2013 Analysis: India’s Supreme Court Upholds Strict Patent Standards and Patients’ Right to Access to Affordable Medicines; Court dismisses unmeritorious court challenge by drug giant


For older news, visit the Access to Medicines news archive


Additional Resources

Essential Action's Access to Medicines Project

Explore Public Citizen's Access to Medicines Program

Trans-Pacific Partnership Agreement (TPP)

Global Kaletra Campaign

Tpp trade negotiators; Flickr image by Gobierno de Chile
The U.S. Trade Representative is pressuring developing countries to trade away access to medicines in the proposed Trans-Pacific Partnership Agreement (TPP). Public Citizen is working for a better partnership.
 
On November 10, public health groups in a dozen countries launched a global campaign to challenge Abbott Laboratories' monopolistic hold on Kaletra (lopinavir + ritonavir), a critical HIV/AIDS medicine.
 
 

Domestic Policy-NIH

Medicine Quality and Anti-Counterfeit Policy


The U.S. government could improve access to medicines by making the medical inventions it funds available for global humanitarian use.   white pills with a blue background; Flickr image by hitoyam
Regulatory policy should promote medicines quality and rational use without compromising access.
 

 

 

Events    |    Presentations    |    Media



For more information on our work, contact us at medsaccess@citizen.org

Follow Public Citizen's Global Access to Medicines Program on Twitter: @PCMedsAccess

Follow Us on Twitter


Please wait while my tweets load

If you can't wait - click here

Copyright © 2013 Public Citizen. All rights reserved. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation.
  Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.